NEW YORK / SINGAPORE — November 8, 2026 — The world’s growing appetite for protein is fueling an investment boom in an industry many consumers rarely think about: the medicines, vaccines, genetics and technologies that keep cattle, pigs and poultry healthy.
As demand for protein-rich food increases, pharmaceutical companies, private-equity investors and technology developers are pouring capital into businesses designed to improve livestock productivity, prevent animal diseases and strengthen the global food supply.
According to Bloomberg’s November 7 report, major animal-health companies including Merck & Co., Zoetis and Elanco Animal Health have accelerated acquisitions and investments aimed at transforming how farmers raise and protect food-producing animals.
The investment surge is being driven by several forces, including rising global population, changing dietary preferences, growing demand for protein-rich foods and the expanding commercial use of livestock-monitoring technology.
In the United States, the trend has received an additional boost from consumers taking weight-loss medications, many of whom are seeking more protein-dense foods to help preserve muscle mass.
The financial consequences are already becoming visible.
Merck acquired poultry-technology company TARGAN for approximately US$650 million, Zoetis announced a US$160-million agreement to acquire Neogen’s animal genomics business, and Elanco expanded its dairy-health operations through the acquisition of AHV International.
Meanwhile, venture-capital investment in livestock management reportedly reached a record US$470 million in 2026 through November 3, according to PitchBook data cited in coverage of the industry.
But as billions of dollars flow into the business of keeping farm animals healthier, a critical question is emerging: Will these investments produce more affordable, reliable food—or primarily create another lucrative growth opportunity for pharmaceutical and technology companies?
Why the World’s Protein Craze Is Transforming Animal Health
Protein has become a major focus of the global food industry.
Consumers are increasingly seeking higher-protein meals, dairy products, snacks and nutritional supplements.
Food manufacturers are responding by introducing products designed to appeal to shoppers interested in fitness, weight management and nutrition.
But the trend extends beyond grocery-store shelves.
Growing demand for meat, eggs and dairy creates additional pressure on farms to produce food efficiently and reliably.
That has brought renewed attention to animal health.
Healthy livestock generally have better prospects for productive growth and reproduction, while effective disease prevention can reduce avoidable losses.
For commercial farmers, preventing illness can be economically important because an outbreak may require expensive treatment, disrupt production or force animals to be culled.
Animal-health companies are consequently investing in technologies that can help farms identify disease earlier, improve livestock management and use veterinary treatments more effectively.
According to Bloomberg, the industry is increasingly attracting interest from pharmaceutical manufacturers and investment firms that previously focused more heavily on other healthcare markets.
Roddy O’Neil, healthcare investment banking executive at Lincoln International, described unusually strong commercial activity surrounding protein production and animal health.
The investment thesis is straightforward.
As demand for animal-derived food grows, companies supplying the technologies used to protect livestock may find new commercial opportunities.
However, rising consumer protein demand does not guarantee that every livestock-health business will experience higher profits.
Investment outcomes will depend on product effectiveness, farmer adoption, regulatory approvals and economic conditions.
Merck Makes a $650-Million Bet on Poultry Technology
One of the clearest examples of the trend is Merck’s acquisition of TARGAN, a company specializing in automated poultry-management technology.
Merck Animal Health announced the proposed transaction in June and subsequently disclosed in its financial reporting that it completed the acquisition in July for approximately US$650 million.
TARGAN develops equipment designed to help commercial hatcheries manage chicks more accurately and efficiently.
Its WingScan technology uses high-resolution imaging and automated analysis to identify and sort chicks by sex.
According to Merck, the technology can process up to 160,000 chicks per hour.
The acquisition also provides access to technology for administering certain vaccines to newly hatched chicks.
These systems are important because poultry producers manage enormous numbers of birds, often within tightly controlled production schedules.
Automated identification, handling and vaccination can help improve consistency and reduce some operational difficulties.
For Merck, the acquisition expands its animal-health business beyond conventional veterinary medicines.
It adds specialized equipment and automation capabilities that could support poultry producers in different markets.
The transaction also demonstrates how the industry is evolving.
Animal-health companies are no longer competing solely through medicines and vaccines.
They are increasingly interested in technologies that influence the broader economics of livestock production.
Merck Expands Animal-Health Manufacturing in Kansas
Merck is also investing heavily in manufacturing capacity.
Bloomberg highlighted an approximately US$895-million expansion at the company’s animal-health manufacturing operations in Kansas.
The project is intended to strengthen manufacturing capabilities and support future demand for animal-health products.
Investments in manufacturing are strategically important because vaccines and veterinary medicines require specialized facilities, quality controls and regulatory compliance.
The development of a new treatment or vaccine does not automatically guarantee that manufacturers can produce sufficient quantities to meet commercial demand.
Production capacity can therefore become an important competitive advantage.
For livestock farmers, dependable access to veterinary products can help reduce the risk of shortages during periods of heightened disease pressure.
However, the Kansas manufacturing investment and TARGAN acquisition are distinct transactions.
Their values should not be combined and described as the price of a single acquisition.
Zoetis Pursues $160-Million Animal Genetics Deal
Zoetis, one of the world’s largest animal-health companies, is pursuing a different part of the livestock technology market.
On March 2, the company announced an agreement to purchase Neogen Corporation’s global animal genomics business for US$160 million, subject to customary adjustments and closing conditions.
The business provides genetic testing and data tools used by livestock producers.
These technologies can help breeders make more informed decisions about animal characteristics, productivity and herd management.
For example, genetic information may help farmers evaluate breeding potential and identify traits relevant to dairy or beef production.
Zoetis said the acquisition would strengthen its precision animal-health operations.
Neogen disclosed that the genomics business generated approximately US$90 million in sales during fiscal 2025.
However, the transaction remained subject to regulatory review and closing requirements in the company’s subsequent disclosures.
It should therefore not be described as fully completed solely because a purchase agreement was announced.
The significance of the deal extends beyond its financial value.
It highlights growing investor interest in the use of data, genetics and predictive tools in livestock production.
Instead of relying entirely on conventional approaches to breeding and animal care, farms may increasingly use data to support management decisions.
But genetic technology does not eliminate the need for proper nutrition, veterinary supervision, biosecurity or responsible farming practices.
Elanco Expands Dairy Health as Cattle Revenue Climbs 12%
Elanco Animal Health is also positioning itself to benefit from stronger interest in livestock productivity.
The company completed its acquisition of AHV International, a Netherlands-based business focused on dairy-cow health, in April 2026.
The acquisition expanded Elanco’s portfolio of products supporting dairy operations.
The financial effects are becoming visible.
In its November 6 third-quarter earnings announcement, Elanco reported that revenue from global ruminants—primarily cattle—had increased 12% year-to-date on an organic, constant-currency basis.
Including the AHV International acquisition and currency movements, reported growth reached approximately 17%.
Those figures refer to different growth calculations and should not be treated as interchangeable.
Elanco also reported third-quarter revenue of approximately US$1.265 billion, representing an 11% year-over-year increase.
The company raised parts of its full-year financial guidance following the results.
Its chief executive, Jeff Simmons, has identified livestock as an important source of future industry growth.
According to Bloomberg, Simmons expects livestock-health market growth of approximately 4% to 7% annually over the remainder of the decade.
That remains a corporate forecast rather than a guaranteed industry outcome.
The wider significance is that demand for animal-health products is increasingly linked to measurable productivity and disease-management needs across commercial farms.
Venture Capital Pours Record $470 Million Into Livestock Technology
The investment boom is extending beyond major pharmaceutical companies.
According to PitchBook figures cited in reporting on the industry, venture-capital investors committed approximately US$470 million globally to livestock management businesses during 2026 through November 3.
Of that amount, approximately US$88 million was directed specifically toward animal-health businesses.
The reported figures represent record investment levels for the relevant categories.
The distinction between the two numbers is important.
Livestock management is a broader category that can include software, monitoring systems, automation and other farm technologies.
Animal health represents a narrower segment focused on products and systems associated with livestock health.
The US$88 million is included within the broader investment activity and should not automatically be added to the US$470-million total.
Startups are developing tools involving animal monitoring, farm data, automated equipment and early detection of health problems.
Some systems aim to identify changes in animal behavior or conditions that may warrant closer inspection by farm personnel or veterinarians.
Others focus on improving how livestock operations record and analyze production information.
These technologies could help farmers improve decision-making.
But many remain subject to commercial testing and adoption challenges.
The record level of venture-capital interest does not mean every technology has demonstrated long-term profitability or scientific effectiveness.
Bird Flu and African Swine Fever Make Disease Prevention a Bigger Business
Growing protein demand is only one part of the story.
Animal diseases remain a major threat to global food production.
Highly pathogenic avian influenza can severely disrupt poultry operations and require the destruction of infected or exposed birds.
African swine fever can cause devastating losses among domestic pigs.
Other livestock diseases and parasites can reduce productivity, raise veterinary costs and complicate international trade.
In May, S&P Global reported warnings from European livestock industry representatives that animal-health investment remained inadequate relative to the economic damage caused by disease outbreaks.
Industry discussions highlighted the risk posed by African swine fever and avian influenza.
Effective prevention can require vaccination where appropriate and authorized, strict biosecurity procedures, disease surveillance and coordinated veterinary responses.
The specific intervention depends on the disease, species and local regulatory framework.
For investors, these risks create commercial demand for veterinary products and monitoring technologies.
For farmers, however, disease prevention is a matter of protecting livelihoods and avoiding losses.
The same commercial trend is directly relevant to the Philippines.
As WWC ONE MEDIA previously reported, Cebu City recorded positive African swine fever tests in pigs, prompting additional containment measures.
Related WWC ONE MEDIA coverage: Cebu City Sounds the Alarm After 10 Pigs Test Positive for ASF — Will the Virus Spread to More Barangays?
The Cebu cases illustrate why access to veterinary services, disease testing and biosecurity remains essential to local livestock production.
Why Animal-Health Products Must Meet Strict Safety Standards
Unlike many other healthcare businesses, livestock-health companies must consider both animal welfare and the safety of food intended for human consumption.
Veterinary treatments used in cattle, pigs and poultry may be subject to restrictions involving dosage, residues and withdrawal periods before meat, milk or eggs can enter the food supply.
Regulatory authorities assess veterinary medicines and other products according to applicable safety and efficacy requirements.
Phibro Animal Health Chief Executive Dani Bendheim has emphasized the commercial complexity of developing products for food-producing animals.
A treatment must be economically practical for farmers while meeting relevant safety standards.
This can create different pricing conditions from those in the companion-animal market.
Pet owners may be willing to spend substantial sums on individual animals.
Commercial livestock producers must generally consider the economics of large herds or flocks.
A veterinary product that costs more than its expected production benefit may struggle to gain widespread adoption.
That places pressure on manufacturers to create treatments and technologies that are both effective and commercially affordable.
For consumers, stronger animal-health standards are important because livestock production is part of the wider food-safety system.
However, healthier livestock does not automatically guarantee that all resulting food products are free from contamination.
Proper processing, storage, transport and food-handling practices remain essential.
Weight-Loss Drugs Are Changing the Protein Market
The rise of GLP-1 weight-loss medications is contributing to the popularity of high-protein foods.
Medicines such as Ozempic and Mounjaro have influenced consumer interest in nutrition and weight management.
Some users seek protein-rich foods to help maintain muscle mass during weight loss.
Reuters reported in October that a Boston Consulting Group survey found GLP-1 users expected to spend approximately 11% more on high-protein foods after beginning treatment.
The survey reflects stated consumer expectations, not proof that all users subsequently increased spending by that amount.
Food companies are responding with new high-protein products, including drinks, snacks, dairy products and prepared meals.
However, demand for protein-rich food does not necessarily translate directly into equivalent increases in beef, pork or poultry consumption.
Protein can come from animal or plant sources, and consumers may satisfy their dietary preferences through dairy, legumes, fortified foods or supplements.
Nutrition specialists also caution that many people already consume adequate amounts of protein.
The presence of a high-protein label does not automatically make a product healthier.
The commercial importance of the trend is that food producers are increasingly competing on protein content, quality and nutritional positioning.
That can indirectly influence investment decisions throughout agricultural supply chains.
The Livestock Boom Could Reshape Food Production in Asia
Asia is an important market for animal protein.
Demand for meat, eggs and dairy is influenced by population growth, income, urbanization, local food preferences and changing diets.
Countries with expanding livestock industries may require greater investment in veterinary services, vaccination programs, disease surveillance and farm-management infrastructure.
However, market conditions vary widely.
Some producers face strong demand while others struggle with high feed prices, disease outbreaks or weak selling prices.
Rabobank’s recent research highlights the uneven outlook across global pork and other animal-protein markets.
The growth of animal-health investment could create opportunities for producers that are able to adopt effective technologies.
But smaller farmers may face barriers involving cost, financing, technical training and access to veterinary expertise.
This is especially relevant in developing markets, where backyard and small-scale livestock production remains economically important.
Improving livestock health therefore requires more than selling advanced technologies.
It also requires accessible veterinary services, farmer education and reliable disease-reporting systems.
Philippines’ ₱148-Million Livestock Project Shows the Local Opportunity
The Philippines is already investing in modernizing parts of its livestock and dairy industries.
In Magsaysay, Davao del Sur, a ₱148.19-million integrated livestock enterprise project is moving forward under the Department of Agriculture’s Philippine Rural Development Project Scale-Up.
The initiative is intended to improve meat processing, dairy production and market opportunities for local farmers.
The project includes improvements connected to slaughterhouse capacity and milk processing.
As previously reported by WWC ONE MEDIA, the investment is designed to address limitations affecting local livestock producers.
Related WWC ONE MEDIA coverage: Magsaysay Moves Ahead With ₱148.19-Million Livestock Project to Transform Local Meat and Dairy Industry
The project demonstrates how investments in livestock infrastructure can influence food safety and agricultural livelihoods.
However, it is separate from the international pharmaceutical acquisitions described by Bloomberg.
Its importance lies in showing how the Philippines is addressing related challenges involving livestock productivity and processing capacity.
Philippine Buffalo Genetics Project Highlights Biotechnology’s Potential
The trend toward precision livestock management also has implications for Philippine dairy production.
In September, the Philippine government inaugurated a ₱237.9-million facility at the Philippine Carabao Center in Science City of Muñoz, Nueva Ecija.
The laboratory specializes in sex-sorting buffalo semen to support breeding programs.
The technology can help producers improve the likelihood of obtaining female offspring for dairy herd expansion.
WWC ONE MEDIA previously examined the facility and its potential role in strengthening domestic dairy production.
Related WWC ONE MEDIA coverage: The Philippines Just Unveiled a World-First Buffalo Lab—And It Could Change the Dairy Industry
The project illustrates the practical value of reproductive biotechnology.
Better breeding tools may support productivity improvements when combined with appropriate animal care, nutrition and farm management.
However, breeding technology alone cannot solve every challenge facing Philippine dairy farmers.
Feed availability, veterinary services, financing and market access remain essential.
Poultry Investment Could Strengthen Local Egg Supply
The Philippines is also supporting smaller-scale poultry enterprises.
In Surigao del Norte, the Department of Agriculture’s Livestock Economic Enterprise Development program provided ₱6.3 million in poultry production support to three farmers’ cooperatives.
Each cooperative received a package valued at approximately ₱2.1 million, including ready-to-lay chickens, housing equipment, feeds, vitamins and veterinary products.
As reported by WWC ONE MEDIA, the initiative is intended to create livelihood opportunities and strengthen local egg production.
Related WWC ONE MEDIA coverage: ₱6.3 Million Livestock Project Lands in Surigao Norte—But What Happens Next Could Change Local Egg Supply
These programs demonstrate that agricultural investment can take many forms.
Large pharmaceutical companies may focus on acquisitions and advanced research.
Local agricultural agencies may prioritize production equipment, basic animal health and community enterprises.
Both approaches depend on the ability to improve productivity and maintain animal welfare.
Will the Protein Boom Make Meat and Eggs More Affordable?
One of the most important questions for consumers is whether increased livestock-health investment will eventually reduce food prices.
In principle, better disease prevention and productivity can reduce some of the costs associated with raising animals.
Fewer disease-related losses may improve the number of healthy animals available for market.
More efficient farm operations can also help producers manage expenses.
But retail food prices depend on many additional factors.
Feed costs, energy prices, transportation expenses, labor, processing capacity, weather conditions and market competition all influence what consumers pay.
A farm may experience better productivity without passing all the savings directly to shoppers.
Companies may also need time to recover the cost of new technologies.
As a result, there is no reliable basis to conclude that the current investment boom will immediately make beef, pork, chicken or eggs cheaper.
The potential benefit is more complex.
Improved livestock health could help make food production more reliable and reduce vulnerability to disease-related disruptions.
Whether consumers see lower prices will depend on conditions throughout the supply chain.
The Biggest Risks Facing Livestock-Health Investors
Despite the industry’s growing appeal, several risks remain.
Regulatory requirements: Veterinary products must satisfy applicable standards for safety and effectiveness, particularly when used in food-producing animals.
Farmer affordability: Producers may avoid adopting technologies whose costs exceed their expected commercial benefits.
Disease uncertainty: Livestock outbreaks can generate demand for veterinary products while simultaneously damaging agricultural production and farm finances.
Integration challenges: Pharmaceutical companies acquiring technology businesses must successfully combine research, manufacturing, distribution and technical expertise.
Market volatility: Meat and dairy prices can change quickly because of consumer demand, trade restrictions, disease outbreaks and feed costs.
Competition: Greater investor interest can lead to higher acquisition valuations and increased pressure on companies to deliver financial returns.
These factors mean that record investment does not guarantee sustained industry-wide profitability.
The key question is whether companies can produce measurable benefits for livestock farmers at commercially sustainable prices.
The Bigger Picture: Is Animal Health Becoming the Next Major Agricultural Investment Opportunity?
The global protein boom is reshaping investment priorities across the food and healthcare industries.
Major companies are acquiring livestock technology businesses.
Venture-capital firms are increasing their exposure to agricultural innovation.
Manufacturers are expanding capacity for veterinary products.
And farmers are facing growing pressure to improve productivity while managing disease and resource constraints.
The trend is supported by long-term forces, including population growth, changing diets and the need for reliable food production.
But there is also uncertainty.
Not every increase in consumer protein demand will translate into greater sales of animal-derived food.
Not every new technology will deliver measurable improvements in productivity.
And not every investment will generate attractive financial returns.
For the Philippines, the trend highlights the importance of stronger veterinary systems, better livestock breeding, poultry disease prevention and affordable farm technologies.
For international investors, it offers a reminder that major commercial opportunities can emerge in industries far removed from the most prominent technology headlines.
The global race to produce more protein is no longer only about raising more cattle, pigs and poultry. It is increasingly about keeping those animals healthier, preventing costly diseases and improving the economics of food production.
But as pharmaceutical companies and investors spend billions expanding their presence in livestock health, the defining question remains:
Will this investment boom deliver a more resilient and affordable global food supply—or will the biggest winners be the companies selling the technology behind the world’s growing appetite for protein?
